SCI Abstract

search
+
18F-FDG brain/cerebellum-to-liver ratios as prognostic factors
We read with great interest the article by Dingli et al. [1] in which they study the ratio of brain to liver 18F-FDG uptak...
Outcomes and prognostic impact of trisomy 8 in acute myeloid leukemia patients treated with intensive chemotherapy
Outcomes and prognostic impact of trisomy 8 in acute myeloid leukemia patients treated with intensive chemotherapy
Cytogenetic aberrations remain a cornerstone of AML classification, prognost...
Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era
Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era
Competing interests Mark D. Ewalt has received speaking fees from Pillar B...
Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study
Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study
Smoldering multiple myeloma (SMM) is a precursor plasma cell disorder charac...
State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee
State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee
In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC)...
Clustering of lymphoid neoplasms by cell of origin, somatic mutation and drug usage profiles: a multi-trait genome-wide association study
Clustering of lymphoid neoplasms by cell of origin, somatic mutation and drug usage profiles: a multi-trait genome-wide association study
Lymphoid neoplasms (LNs) are heterogeneous malignancies arising from lymphoid cells, displaying diverse clinical and molec...
Pediatric MDS in GATA2 deficiency, narrowing the scope
Kotmayer L, Kozyra EJ, Kang G, Strahm B, Yoshimi A, Sahoo SS, et al. Age-dependent phenotypic and molecular evolution of p...
Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
Autologous stem cell transplantation (ASCT) is a key therapeutic strategy for many patients diagnosed with multiple myelom...
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
Response and progression criteria are necessary for any malignancy to standa...
Efficacy and safety of CAR-T cell therapy in B-ALL patients previously treated with blinatumomab
Efficacy and safety of CAR-T cell therapy in B-ALL patients previously treated with blinatumomab
Accumulating evidence suggests that blinatumomab (a CD3-CD19 bispecific T-ce...
Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases
Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases
Anemia after allogeneic hematopoietic stem cell transplantation (allo-HSCT) ...
Genomic characterization of chronic lymphocytic leukemia in patients of African ancestry
Genomic characterization of chronic lymphocytic leukemia in patients of African ancestry
Despite the considerable effort to characterize the genomic landscape of chronic lymphocytic leukemia (CLL), published dat...
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Patients with relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and a need remains for novel effective the...
Defining ‘Intention’ in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4....
Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients
Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients
CBF-AMLs, which account for approximately 12–15% of all AML cases, involve c...
Correction: A simplified, two-factor clinical prognostic scoring system for patients with newly diagnosed Hodgkins Lymphoma
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4....
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial
Given the early use of triplet and quadruplet regimens, most patients with multiple myeloma (MM) will be exposed and/or re...
Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma
Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma
Multiple myeloma (MM) is a hematological malignancy whose curability is greatly challenged by recurrent patient relapses a...
Bispecific antibodies in the treatment of multiple myeloma
Bispecific antibodies in the treatment of multiple myeloma
The treatment paradigm in myeloma is constantly changing. Upfront use of monoclonal antibodies like daratumumab along with...
Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma
Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma
First-line treatment for advanced-stage diffuse large B-cell lymphoma (DLBCL) typically involves 6x R-CHOP21 or 6x R-CHOP2...
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients
Lenalidomide, bortezomib, and dexamethasone (RVd) have previously been established as standard-of-care induction therapy f...
Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia
Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia
Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutations ...
Multiomic analysis identifies a high-risk subgroup that predicts poor prognosis in t(8;21) acute myeloid leukemia
Multiomic analysis identifies a high-risk subgroup that predicts poor prognosis in t(8;21) acute myeloid leukemia
Begna KH, Xu X, Gangat N, Alkhateeb H, Patnaik MM, Al-Kali A, et al. Core-binding factor acute myeloid leukemia: long-term...
Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy
Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy
Therapy-related acute myeloid leukemia (t-AML) often exhibits adverse (genetic) features. There is ongoing discussion on t...
Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison
Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison
Competing interests MS reports receiving funding from BeiGene paid to Fred...
A comprehensive approach to evaluate genetic abnormalities in multiple myeloma using optical genome mapping
A comprehensive approach to evaluate genetic abnormalities in multiple myeloma using optical genome mapping
Multiple myeloma (MM) is a plasma cell neoplasm (PCN) [1]. Sensitive and accurate identification of g...
Machine learning analysis of gene expression reveals TP53 Mutant-like AML with wild type TP53 and poor prognosis
Machine learning analysis of gene expression reveals TP53 Mutant-like AML with wild type TP53 and poor prognosis
TP53 mutations (TP53Mut) define the most rapidly fatal AML subtype [1, 2] (Supplementary Fig. S1A). We used AML datasets (...
The landscape of NUP98 rearrangements clinical characteristics and treatment response from 1491 acute leukemia patients
The landscape of NUP98 rearrangements clinical characteristics and treatment response from 1491 acute leukemia patients
Nucleoporin 98 (NUP98, chromosome 11p15) fusion oncoproteins also called NUP98 rearrangements (NUP98r...
T cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity “graft-versus-leukemia effects”
T cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity “graft-versus-leukemia effects”
BCL-2, a crucial regulator of the mitochondrial apoptotic pathway, maintains myeloblast survival by s...
Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients
Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients
CAR-T cell therapy has led to a significant advance in the treatment of refractory/relapsed diffuse l...
Load More
format_indent_increase